Legend Biotech Earnings Call Highlights CARVYKTI Momentum

Legend Biotech Corporation ((LEGN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Legend Biotech’s latest earnings call struck a notably upbeat tone, as management paired rapid sales growth with improving profitability and compelling clinical data for its flagship CAR-T therapy, CARVYKTI. While executives acknowledged safety, manufacturing and competitive risks, they stressed that strong execution, expanding capacity and deepening market adoption are driving a favorable long‑term trajectory.

Strong CARVYKTI Sales Growth

CARVYKTI continued to power Legend’s top line, with fourth‑quarter 2025 net trade sales of about $555 million, up 66% year over year and 6% sequentially. U.S. sales reached $420 million, rising 38% from a year ago, while ex‑U.S. revenue tripled to $135 million, underscoring growing international demand for the multiple myeloma therapy.

Robust Overall Revenue and Margins

Total company revenue climbed to $306 million in the quarter, a 64% jump from the prior year, reflecting broad momentum beyond headline CARVYKTI numbers. Gross margin held firm at 61% overall, with CARVYKTI product margin at 57% and stabilizing around that level in recent quarters, supporting a more predictable earnings profile.

Operating and Adjusted Profitability Trajectory

Legend is closing in on full profitability as operating margin improved dramatically from –142% in mid‑2023 to –6% in Q4 2025, with operating loss narrowing to roughly –$20 million. On an adjusted basis, the company swung to a modest profit, posting $2.5 million in adjusted net income and $0.01 in adjusted diluted EPS versus a sizable loss a year earlier.

Large Patient Base and Global Footprint

More than 10,000 multiple myeloma patients have now been treated with CARVYKTI, giving Legend a substantial real‑world data set and brand presence. The therapy is available at 294 treatment sites across 14 markets, including 145 U.S. centers where about one‑third are community hospitals and roughly 80% of patients live within 50 miles of a site.

Manufacturing Capacity and Success Rates

Current installed capacity supports production of around 10,000 CARVYKTI doses annually, and with partner J&J the company plans to push that figure toward roughly 20,000 over time. Commercial manufacturing between July 2024 and October 2025 delivered a roughly 99% success rate overall, with out‑of‑spec product modestly higher in heavily pretreated patients but trending better as processes improve.

Compelling Long-Term Clinical Data

Updated CARTITUDE analyses showcased durable efficacy, with triple‑class exposed patients who had received three prior lines of therapy achieving a median progression‑free survival of 50.4 months after a single CARVYKTI infusion. In the CARTITUDE‑4 study’s standard‑risk group, 80% of patients remained progression‑free and off treatment at 2.5 years, and among those progression‑free at one year, 93% were still progression‑free and alive at 2.5 years.

Pipeline and Development Momentum

Management highlighted a growing pipeline beyond CARVYKTI, including LUCAR‑G39D, an allogeneic gamma delta CAR‑T that has shown manageable safety and encouraging early activity. Legend also advanced its first in vivo CAR‑T program from candidate selection to initial patient dosing in about six months and plans to file one to two new U.S. investigational applications by year‑end, with early clinical data targeted for mid‑2026.

Balance Sheet and Cash Position

The company ended the year with $949 million in cash, cash equivalents and time deposits, giving it ample runway to fund trials and capacity expansion. Operating cash outflow improved sharply to $12 million in the quarter from $82 million a year earlier, providing financial flexibility to invest in in vivo platforms, business development and manufacturing upgrades.

Commercial Adoption Trends Favor Earlier Lines

Adoption patterns are shifting toward earlier treatment lines, with about 65% of CARVYKTI patients now treated in the second through fourth line setting and roughly half of prescribing occurring in the outpatient environment. The fastest growth is coming from second and third line segments, aligning with Legend’s strategy to move CARVYKTI earlier in the multiple myeloma treatment algorithm.

Delayed Neurotoxicity / Parkinsonism Risk in Class

Management addressed class‑wide concerns about delayed neurotoxicity, including Parkinsonism‑like events observed with CAR‑T therapies such as CARVYKTI. Data from a Stanford cohort found 22 Parkinsonism cases among 761 patients, with 21 occurring in those who did not respond to bridging therapy, underscoring the importance of effective bridging regimens and continued physician education to mitigate risk.

Out-of-Spec Rates Higher in Later-Line Patients

Legend’s commercial manufacturing review showed that out‑of‑specification rates rise with heavier pretreatment, reaching about 9.2% in patients with four or more prior lines of therapy versus roughly 6.5% in those treated after one to three lines. This pattern highlights manufacturing challenges in sicker populations and reinforces the strategic push to treat patients earlier, where product consistency is stronger.

Competitive and Regulatory Uncertainties

Executives acknowledged increasing competition from other cell therapies and bispecific antibodies, as well as the impact of recent deal‑making in the space. They also noted regulatory uncertainty around using minimal residual disease as a registration endpoint for CAR‑T products, since existing guidance is largely based on non‑CAR‑T modalities and leaves limited precedent for accelerated approvals built on MRD.

Gross Margin Plateau and Cost Dynamics

Despite scale‑up, CARVYKTI’s gross margin has flattened around 57% in recent quarters, indicating that major cost efficiencies have yet to fully flow through. Management expects the ramp‑up of its Tech Lane facility and broader network efficiencies to gradually reduce cost of goods sold, which could support margin expansion if pricing and mix remain favorable.

Operating Loss and Remaining Profitability Risk

While the CARVYKTI franchise itself is now profitable and adjusted company results are in the black, Legend still posts a small operating loss at the consolidated level. Investors are watching the company’s stated goal of achieving full‑year profitability in 2026, a milestone that hinges on maintaining momentum in sales growth, cost control and pipeline execution.

Growth Requires Continued Site Activation and Education

Management stressed that BCMA‑targeted therapies still penetrate less than 5% of eligible patients in the second through fourth lines and under 10% in the fifth line, leaving a large untapped market. To close this gap, Legend is investing in sales, medical education and payer outreach, which drove a 22% increase in SG&A but is seen as critical to unlocking long‑term growth.

Guidance and Forward-Looking Outlook

For 2026, Legend guided to sequential CARVYKTI growth in all four quarters and expressed confidence in delivering roughly 50% year‑over‑year top‑line expansion, underpinned by robust demand and expanding capacity. Management expects company‑wide profitability next year, sees peak CARVYKTI sales potential above $5 billion and plans to scale production capacity toward about 20,000 doses annually while advancing one to two new U.S. clinical programs.

Legend Biotech’s earnings call painted a picture of a company transitioning from high‑growth story to an emerging profit generator, anchored by a differentiated CAR‑T asset and a rich pipeline. For investors, the appeal lies in sustained revenue expansion and strong clinical data, balanced against safety, manufacturing and competitive risks that management insists are manageable with continued execution.